637 related articles for article (PubMed ID: 23299535)
1. Cancer heterogeneity: implications for targeted therapeutics.
Fisher R; Pusztai L; Swanton C
Br J Cancer; 2013 Feb; 108(3):479-85. PubMed ID: 23299535
[TBL] [Abstract][Full Text] [Related]
2. Tumour heterogeneity and drug resistance: personalising cancer medicine through functional genomics.
Lee AJ; Swanton C
Biochem Pharmacol; 2012 Apr; 83(8):1013-20. PubMed ID: 22192819
[TBL] [Abstract][Full Text] [Related]
3. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine.
Gerlinger M; Swanton C
Br J Cancer; 2010 Oct; 103(8):1139-43. PubMed ID: 20877357
[TBL] [Abstract][Full Text] [Related]
4. Intra-tumour genetic heterogeneity and poor chemoradiotherapy response in cervical cancer.
Cooke SL; Temple J; Macarthur S; Zahra MA; Tan LT; Crawford RA; Ng CK; Jimenez-Linan M; Sala E; Brenton JD
Br J Cancer; 2011 Jan; 104(2):361-8. PubMed ID: 21063398
[TBL] [Abstract][Full Text] [Related]
5. [Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].
Ludwig WD
Z Evid Fortbild Qual Gesundhwes; 2012; 106(1):11-22. PubMed ID: 22325103
[TBL] [Abstract][Full Text] [Related]
6. Tumour heterogeneity and the evolution of polyclonal drug resistance.
Burrell RA; Swanton C
Mol Oncol; 2014 Sep; 8(6):1095-111. PubMed ID: 25087573
[TBL] [Abstract][Full Text] [Related]
7. Reading between the lines; understanding drug response in the post genomic era.
Alifrangis CC; McDermott U
Mol Oncol; 2014 Sep; 8(6):1112-9. PubMed ID: 24957465
[TBL] [Abstract][Full Text] [Related]
8. Intra-tumour heterogeneity - going beyond genetics.
Caiado F; Silva-Santos B; Norell H
FEBS J; 2016 Jun; 283(12):2245-58. PubMed ID: 26945550
[TBL] [Abstract][Full Text] [Related]
9. Implementing Genome-Driven Oncology.
Hyman DM; Taylor BS; Baselga J
Cell; 2017 Feb; 168(4):584-599. PubMed ID: 28187282
[TBL] [Abstract][Full Text] [Related]
10. Not Everyone Fits the Mold: Intratumor and Intertumor Heterogeneity and Innovative Cancer Drug Design and Development.
Dzobo K; Senthebane DA; Thomford NE; Rowe A; Dandara C; Parker MI
OMICS; 2018 Jan; 22(1):17-34. PubMed ID: 29356626
[TBL] [Abstract][Full Text] [Related]
11. Tumour heterogeneity and resistance to cancer therapies.
Dagogo-Jack I; Shaw AT
Nat Rev Clin Oncol; 2018 Feb; 15(2):81-94. PubMed ID: 29115304
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response.
Haragan A; Field JK; Davies MPA; Escriu C; Gruver A; Gosney JR
Lung Cancer; 2019 Aug; 134():79-84. PubMed ID: 31320000
[TBL] [Abstract][Full Text] [Related]
13. Single-cell sequencing and its applications in bladder cancer.
Wei W; Rong Y; Sanhe L; Chunxiu Y; Thokerunga E; Cui D; Wang F
Expert Rev Mol Med; 2022 Jan; 24():e6. PubMed ID: 35086606
[TBL] [Abstract][Full Text] [Related]
14. Tumour heterogeneity and immune-modulation.
Jamal-Hanjani M; Thanopoulou E; Peggs KS; Quezada SA; Swanton C
Curr Opin Pharmacol; 2013 Aug; 13(4):497-503. PubMed ID: 23664091
[TBL] [Abstract][Full Text] [Related]
15. Translating genomics to the clinic: implications of cancer heterogeneity.
Samuel N; Hudson TJ
Clin Chem; 2013 Jan; 59(1):127-37. PubMed ID: 23151419
[TBL] [Abstract][Full Text] [Related]
16. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
17. Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours.
Khalique L; Ayhan A; Weale ME; Jacobs IJ; Ramus SJ; Gayther SA
J Pathol; 2007 Feb; 211(3):286-95. PubMed ID: 17154249
[TBL] [Abstract][Full Text] [Related]
18. Intra-tumour heterogeneity: a looking glass for cancer?
Marusyk A; Almendro V; Polyak K
Nat Rev Cancer; 2012 Apr; 12(5):323-34. PubMed ID: 22513401
[TBL] [Abstract][Full Text] [Related]
19. Tumour Heterogeneity: The Key Advantages of Single-Cell Analysis.
Tellez-Gabriel M; Ory B; Lamoureux F; Heymann MF; Heymann D
Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27999407
[TBL] [Abstract][Full Text] [Related]
20. The challenge of intratumour heterogeneity in precision medicine.
Seoane J; De Mattos-Arruda L
J Intern Med; 2014 Jul; 276(1):41-51. PubMed ID: 24661605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
